Table 1 Baseline Characteristics of 6-months finishers divided by intervention group.
RT (n = 23–30) | RTS (n = 21–23) | CT (n = 20–26) | Total (n = 64–79) | |
|---|---|---|---|---|
Age (years) | 82 ± 6 | 81 ± 8 | 84 ± 5 | 83 ± 6 |
BMI (kg/m 2 ) | 28.97 ± 3.86 | 29.41 ± 5.31 | 27.94 ± 5.12 | 28.76 ± 4.72 |
NDI | 1.95 ± 0.08 | 1.98 ± 0.06 | 1.98 ± 0.07 | 1.97 ± 0.07 |
MNi frequency/1000 BN cells | 28.60 ± 15.60 | 28.17 ± 18.43 | 23.70 ± 9.53 | 26.90 ± 14.90 |
NPBs/1000 BN cells | 1.17 ± 1.21 | 0.93 ± 0.88 | 1.36 ± 1.03 | 1.16 ± 1.06 |
NBuds/1000 BN cells | 3.47 ± 2.67 | 3.35 ± 2.46 | 4.42 ± 4.85 | 3.74 ± 3.46 |
Stand-up Test (repetitions) | 12.31 ± 3.07 | 13.77 ± 4.28 | 12.13 ± 4.44 | 12.68 ± 3.92 |
6 min Walking Test (m) | 384 ± 79 | 373 ± 99 | 382 ± 97 | 380 ± 90 |
Body Fat (%) | 33.87 ± 7.36 | 33.89 ± 9.14 | 32.59 ± 9.69 | 33.48 ± 8.55 |
Glucose (mg/dl) | 108 ± 25 | 99 ± 11 | 107 ± 22 | 105 ± 21 |
hs-Insulin (μIU/ml) | 9.77 ± 6.91 | 10.43 ± 6.33 | 8.60 ± 7.74 | 9.58 ± 6.98 |
Cholesterol (mg/dl) | 205 ± 41 | 209 ± 37 | 205 ± 38 | 206 ± 38 |
HDL (mg/dl) | 62.57 ± 14.03 | 66.74 ± 17.88 | 63.69 ± 20.09 | 64.15 ± 17.20 |
LDL (mg/dl) | 120 ± 37 | 119 ± 39 | 118 ± 32 | 119 ± 35 |
Chol/HDL Ratio (%) | 3.40 ± 0.86 | 3.33 ± 1.01 | 3.45 ± 0.95 | 3.40 ± 0.92 |
Triglycerides (mg/dl) | 113 ± 38 | 118 ± 45 | 114 ± 47 | 115 ± 43 |
Lipoprotein A1 (mg/dl) | 16.22 ± 19.66 | 36.85 ± 50.70 | 26.42 ± 37.69 | 25.58 ± 37.35 |
hs-CRP (mg/l) | 6.50 ± 13.27 | 5.66 ± 9.08 | 3.96 ± 4.02 | 5.42 ± 9.75 |
UCB (μmol/l) | 8.75 ± 5.68* | 6.15 ± 3.33 | 6.35 ± 2.13 | 7.16 ± 4.20 |
hsTroponin-T (ng/ml) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.02 ± 0.02 | 0.01 ± 0.02 |
NT-pro BNP (pg/ml) | 393 ± 779 | 280 ± 370 | 467 ± 672 | 385 ± 644 |
cfDNA (ng/ml) | 185 ± 47 | 197 ± 55 | 185 ± 62 | 188 ± 54 |
MDA (μmol/l) | 1.97 ± 0.42 | 1.89 ± 0.44 | 1.89 ± 0.36 | 1.92 ± 0.41 |
Telomere Length (kb) | 2.92 ± 1.16 | 2.76 ± 1.63 | 3.05 ± 0.94 | 2.91 ± 1.27 |
